BR112022007035A2 - Sais de um composto e formas cristalinas dos mesmos - Google Patents

Sais de um composto e formas cristalinas dos mesmos

Info

Publication number
BR112022007035A2
BR112022007035A2 BR112022007035A BR112022007035A BR112022007035A2 BR 112022007035 A2 BR112022007035 A2 BR 112022007035A2 BR 112022007035 A BR112022007035 A BR 112022007035A BR 112022007035 A BR112022007035 A BR 112022007035A BR 112022007035 A2 BR112022007035 A2 BR 112022007035A2
Authority
BR
Brazil
Prior art keywords
compound
crystalline forms
salts
same
present
Prior art date
Application number
BR112022007035A
Other languages
English (en)
Portuguese (pt)
Inventor
Li Wenji
Feng Ling
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of BR112022007035A2 publication Critical patent/BR112022007035A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022007035A 2019-10-14 2020-10-13 Sais de um composto e formas cristalinas dos mesmos BR112022007035A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910973785 2019-10-14
PCT/CN2020/120594 WO2021073494A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Publications (1)

Publication Number Publication Date
BR112022007035A2 true BR112022007035A2 (pt) 2022-06-28

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007035A BR112022007035A2 (pt) 2019-10-14 2020-10-13 Sais de um composto e formas cristalinas dos mesmos

Country Status (14)

Country Link
US (2) US12559472B2 (cg-RX-API-DMAC7.html)
EP (1) EP4045484A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022552329A (cg-RX-API-DMAC7.html)
KR (1) KR20220088712A (cg-RX-API-DMAC7.html)
CN (3) CN119751422A (cg-RX-API-DMAC7.html)
AR (1) AR120202A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020367905A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154064A1 (cg-RX-API-DMAC7.html)
IL (1) IL292206B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004274A (cg-RX-API-DMAC7.html)
TW (1) TWI895290B (cg-RX-API-DMAC7.html)
UA (1) UA129777C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021073494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450499A4 (en) * 2021-12-13 2025-12-17 Abbisko Therapeutics Co Ltd FGFR4-inhibitoric acid salt, manufacturing process and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
CN107660200B (zh) * 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN110023318A (zh) * 2016-12-01 2019-07-16 和记黄埔医药(上海)有限公司 化合物的晶型

Also Published As

Publication number Publication date
TWI895290B (zh) 2025-09-01
CN114555558B (zh) 2024-12-17
CN114555558A (zh) 2022-05-27
EP4045484A1 (en) 2022-08-24
WO2021073494A1 (en) 2021-04-22
IL292206B2 (en) 2026-03-01
US20230121346A1 (en) 2023-04-20
CA3154064A1 (en) 2021-04-22
EP4045484A4 (en) 2023-09-06
JP2025143319A (ja) 2025-10-01
US20260138967A1 (en) 2026-05-21
IL292206B1 (en) 2025-11-01
UA129777C2 (uk) 2025-07-30
US12559472B2 (en) 2026-02-24
CN119751422A (zh) 2025-04-04
CN119462616A (zh) 2025-02-18
AU2020367905A1 (en) 2022-04-21
IL292206A (en) 2022-06-01
MX2022004274A (es) 2022-05-06
TW202128669A (zh) 2021-08-01
JP2022552329A (ja) 2022-12-15
KR20220088712A (ko) 2022-06-28
AR120202A1 (es) 2022-02-02

Similar Documents

Publication Publication Date Title
PH12021552048A1 (en) Jak inhibitor compound and use thereof
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
UY38144A (es) Inhibidores de la señalización mediada por tirosina cinasa
MX2016002185A (es) Formulacion combinada de dos compuestos antivirales.
BR112015021027A2 (pt) compostos terapêuticos
BR112015014222A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica
MX2021002199A (es) Inhibidores de sarcomeros cardiacos.
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112014009190A8 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
EA201401084A1 (ru) Соли 5-[(1r)-2({2-[4-(2,2-дифтор-2-фенилэтокси)фенил]этил}амино)-1-гидроксиэтил]-8-гидроксихинолин-2(1н)-она
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
EA201991595A1 (ru) Активатор nrf2
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
BR112022005736A2 (pt) Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
BR112023000065A2 (pt) Sal e forma cristalina de composto de pirimidina e métodos de preparação para os mesmos
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]